Eli Lilly and Company

Eli Lilly Company

David B Flora

Richard Dennis DiMarchi

William F Heath, Jr

David L Smiley

James E Shields

James A Hoffmann

Brigitte E Schoner

Margret B Basinski

James A Hoffman

Fatty acid-acylated insulin analogs are soluble at moderately acidic pH and provide long-acting basal control of glucose levels. In such a molecule, the insulin analog portion comprises an insulin A-chain, or an analog thereof, properly cross-linked to an analog of the insulin B-chain, wherein the &egr;-amino group of a Lys residue at either positions 28 or 29 of the B-chain analog is acylated with a fatty acid. The insulin analog portion of the molecules comprises an A-chain of insulin, or an analog thereof, with an optional Arg at position 0, properly cross-linked to a B-chain analog that includes Arg at positions 31 and 32.

Fatty acid-acylated insulin analogs

The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

Anti-obesity proteins

Growing community of inventors

Greenfield, IN, United States of America

David B Flora